PAX7 Targets, CD54, Integrin α9β1, and SDC2, Allow Isolation of Human ESC/iPSC-Derived Myogenic Progenitors

Alessandro Magli, Tania Incitti, James Kiley, Scott A. Swanson, Radbod Darabi, Fabrizio Rinaldi, Sridhar Selvaraj, Ami Yamamoto, Jakub Tolar, Ce Yuan, Ron Stewart, James A. Thomson, Rita C.R. Perlingeiro

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Pluripotent stem (PS)-cell-derived cell types hold promise for treating degenerative diseases. However, PS cell differentiation is intrinsically heterogeneous; therefore, clinical translation requires the development of practical methods for isolating progenitors from unwanted and potentially teratogenic cells. Muscle-regenerating progenitors can be derived through transient PAX7 expression. To better understand the biology, and to discover potential markers for these cells, here we investigate PAX7 genomic targets and transcriptional changes in human cells undergoing PAX7-mediated myogenic commitment. We identify CD54, integrin α9β1, and Syndecan2 (SDC2) as surface markers on PAX7-induced myogenic progenitors. We show that these markers allow for the isolation of myogenic progenitors using both fluorescent- and CGMP-compatible magnetic-based sorting technologies and that CD54+α9β1+SDC2+ cells contribute to long-term muscle regeneration in vivo. These findings represent a critical step toward enabling the translation of PS-cell-based therapies for muscle diseases.

Original languageEnglish (US)
Pages (from-to)2867-2877
Number of pages11
JournalCell reports
Issue number13
StatePublished - Jun 27 2017

Bibliographical note

Funding Information:
This project was supported by NIH grants R01 AR055299 (to R.C.R.P.) and U01 HL100407R01 (to R.C.R.P. and J.A.T.), the Greg Marzolf Jr. Foundation (to R.C.R.P.), ADVault, Inc. and (to R.C.R.P.), and by Regenerative Medicine Minnesota MRM 2015 PDSCH 003 (to A.M.). The cytogenetic analyses were performed in the Cytogenomics Shared Resource at the University of Minnesota, with support from the comprehensive Masonic Cancer Center NIH grant #P30 CA077598-09. The authors thank Dr. Jaemin Kim for his assistance with the serum-free differentiation protocol and Dr. Nelio Oliveira for his assistance with the teratoma experiments.

Publisher Copyright:
© 2017 The Author(s)


  • CD54
  • ChIP sequencing
  • PAX7
  • RNA sequencing
  • SDC2
  • integrin α9β1
  • muscle regeneration
  • muscular dystrophy
  • skeletal myogenesis
  • stem cell therapy


Dive into the research topics of 'PAX7 Targets, CD54, Integrin α9β1, and SDC2, Allow Isolation of Human ESC/iPSC-Derived Myogenic Progenitors'. Together they form a unique fingerprint.

Cite this